Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1243378 | 0.90 | GRM5 (0.56) | GRM5 | |
| SCHEMBL8240889 | 0.87 | GRM5 (0.61) | GRM5 | |
| SCHEMBL1244471 | 0.87 | GRM5 (0.57) | GRM5 | |
| SCHEMBL1241695 | 0.85 | GRM5 (0.72) | GRM5 | |
| SCHEMBL1241749 | 0.85 | GRM5 (0.57) | GRM5 | |
| SCHEMBL3958791 | 0.85 | GRM5 (0.55) | GRM5 | |
| SCHEMBL11966051 | 0.78 | GRM5 (0.65) | GRM5 | |
| SCHEMBL11966020 | 0.77 | GRM5 (0.71) | GRM5 | |
| SCHEMBL5653485 | 0.76 | GRM5 (1.00) | GRM5 | |
| SCHEMBL1243365 | 0.75 | GRM5 (0.69) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609852-B2 | Thiazolyl mGluR5 antagonists and methods for their use | MERCK SHARP & DOHME CORP. (US) | 2013-12-17 | — | — | US | disclosed |
| EP-2380889-B1 | Thiazolyl MGLUR5 antagonists and methods for their use | MERCK SHARP & DOHME (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20120289696-A1 | THIAZOLYL MGLUR5 ANTAGONISTS AND METHODS FOR THEIR USE | MERCK SHARP & DOHME LLC | 2012-11-15 | — | — | US | disclosed |
| US-20120289696-A1 | THIAZOLYL MGLUR5 ANTAGONISTS AND METHODS FOR THEIR USE | MERCK SHARP & DOHME LLC | 2012-11-15 | — | — | US | disclosed |
| US-8242143-B2 | Thiazolyl mGluR5 antagonists and methods for their use | MERCK SHARP & DOHME CORP. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242143-B2 | Thiazolyl mGluR5 antagonists and methods for their use | MERCK SHARP & DOHME CORP. (US) | 2012-08-14 | — | — | US | disclosed |
| EP-2380889-A2 | Thiazolyl MGLUR5 antagonists and methods for their use | Merck Sharp & Dohme Corp. (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110230526-A1 | Thiazolyl Mglur5 Antagonists and Methods for Their Use | MERCK SHARP & DOHME CORP. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230526-A1 | Thiazolyl Mglur5 Antagonists and Methods for Their Use | MERCK SHARP & DOHME CORP. (US) | 2011-09-22 | — | — | US | disclosed |
| US-7879882-B2 | glutamate receptor antagonists such as 3-fluoro-5-[5-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridin-2-yl]benzonitrile, used for the treatment of ischemia, , schizophrenia, obesity, attention deficit disorders, epilepsy, eating, cardiovacular, neurodegenerative, psychological and sleep disorders | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7879882-B2 | glutamate receptor antagonists such as 3-fluoro-5-[5-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridin-2-yl]benzonitrile, used for the treatment of ischemia, , schizophrenia, obesity, attention deficit disorders, epilepsy, eating, cardiovacular, neurodegenerative, psychological and sleep disorders | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7879882-B2 | glutamate receptor antagonists such as 3-fluoro-5-[5-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridin-2-yl]benzonitrile, used for the treatment of ischemia, , schizophrenia, obesity, attention deficit disorders, epilepsy, eating, cardiovacular, neurodegenerative, psychological and sleep disorders | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090203903-A1 | Thiazolyl mglur5 antagonists and methods for their use | MERCK SHARP & DOHME LLC | 2009-08-13 | — | — | US | disclosed |
| US-20090203903-A1 | Thiazolyl mglur5 antagonists and methods for their use | MERCK SHARP & DOHME LLC | 2009-08-13 | — | — | US | disclosed |
| US-20090203903-A1 | Thiazolyl mglur5 antagonists and methods for their use | MERCK SHARP & DOHME LLC | 2009-08-13 | — | — | US | disclosed |
| EP-1893608-A4 | THIAZOLYL MGLUR5 ANTAGONISTS AND METHODS FOR THEIR USE | MERCK & CO INC (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1893608-A2 | THIAZOLYL MGLUR5 ANTAGONISTS AND METHODS FOR THEIR USE | Merck and Co., Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007050050-A2 | THIAZOLYL MGLUR5 ANTAGONISTS AND METHODS FOR THEIR USE | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007050050-A2 | THIAZOLYL MGLUR5 ANTAGONISTS AND METHODS FOR THEIR USE | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289696-A1 | THIAZOLYL MGLUR5 ANTAGONISTS AND METHODS FOR THEIR USE | GRM5, GRIK5, GRM3 | GRM5 1/4885 |
| US-20090203903-A1 | Thiazolyl mglur5 antagonists and methods for their use | GRM5, GRIK5, GRM3 | GRM5 1/4885 |
| US-20110230526-A1 | Thiazolyl Mglur5 Antagonists and Methods for Their Use | GRM5, GRIK5, GRM3 | GRM5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.